Phase 2 Study of the Safety and Pharmacokinetics of Carfilzomib in Subjects with Relapsed refractory Multiple Myeloma and Various Degrees of Renal Dysfunction (Proteolix, Inc. PX-171-005)

Trial Profile

Phase 2 Study of the Safety and Pharmacokinetics of Carfilzomib in Subjects with Relapsed refractory Multiple Myeloma and Various Degrees of Renal Dysfunction (Proteolix, Inc. PX-171-005)

Completed
Phase of Trial: Phase II

Latest Information Update: 04 May 2017

At a glance

  • Drugs Carfilzomib (Primary)
  • Indications Multiple myeloma
  • Focus Pharmacokinetics
  • Sponsors Amgen; Onyx Pharmaceuticals
  • Most Recent Events

    • 07 Dec 2016 Results of a population pharmacokinetic model analysis and exposure response analysis based on pooled data from PX171-003, PX171-004, PX171-005, PX171-006, PX171-007, ASPIRE, ENDEAVOR, CFZ001 and CFZ002 studies published in the Journal of Clinical Pharmacology.
    • 06 Nov 2012 Data from four phase II trials will be presented at the 54th American Society of Hematology Annual Meeting (abstract #4037), according to an Onyx Pharmaceuticals media release.
    • 17 May 2012 Haematologic safety data will be presented at the 48th American Society of Clinical Oncology Annual Meeting (ASCO), according to an Onyx Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top